Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

130Citations
Citations of this article
123Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Bardoxolone methyl, an Nrf2-activating and nuclear factor-κB-inhibiting semisynthetic oleanane triterpenoid compound, was evaluated in a phase 3 trial (BEACON) in patients with type 2 diabetes mellitus (T2DM) and stage 4 chronic kidney disease (CKD). The trial was terminated because of an increase in heart failure events in the bardoxolone methyl group, many of which appeared related to fluid retention. Thus, additional analyses were conducted to explain these serious adverse events. Methods: Patients (n = 2,185) were randomized to receive once-daily bardoxolone methyl (20 mg) or placebo. Twenty-four-hour urine collections were analyzed in a subset of the BEACON population and from a separate, open-label pharmacology study in patients with stage 3b/4 CKD and T2DM administered 20 mg bardoxolone methyl once daily for 56 consecutive days. Results: Bardoxolone-methyl-treated patients in the BEACON substudy had a clinically meaningful reduction in urine volume and sodium excretion at week 4 relative to baseline (p < 0.05), and a separate study revealed that decreased sodium excretion and urine output occurred in some patients with stage 4 CKD but not those with stage 3b CKD. The clinical phenotype of fluid overload and heart failure in BEACON was similar to that observed with endothelin receptor antagonists in advanced CKD patients, and preclinical data demonstrate that bardoxolone methyl modifies endothelin signaling. Conclusions: The totality of the evidence suggests that through modulation of the endothelin pathway, bardoxolone methyl may pharmacologically promote acute sodium and volume retention and increase blood pressure in patients with more advanced CKD. © 2014 S. Karger AG, Basel.

References Powered by Scopus

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort

1242Citations
N/AReaders
Get full text

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

866Citations
N/AReaders
Get full text

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

805Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The molecular mechanisms regulating the KEAP1-NRF2 pathway

904Citations
N/AReaders
Get full text

Oxidative stress in chronic kidney disease

553Citations
N/AReaders
Get full text

Nrf2, the master regulator of anti-oxidative responses

534Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chin, M. P., Reisman, S. A., Bakris, G. L., O’Grady, M., Linde, P. G., McCullough, P. A., … Meyer, C. J. (2014). Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. American Journal of Nephrology, 39(6), 499–508. https://doi.org/10.1159/000362906

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 29

44%

Researcher 27

41%

Professor / Associate Prof. 8

12%

Lecturer / Post doc 2

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 32

48%

Biochemistry, Genetics and Molecular Bi... 14

21%

Agricultural and Biological Sciences 13

20%

Pharmacology, Toxicology and Pharmaceut... 7

11%

Article Metrics

Tooltip
Mentions
References: 1

Save time finding and organizing research with Mendeley

Sign up for free